In a significant boost for 23andMe, the Food and Drug Administration has allowed the direct-to-consumer genetics Silicon Valley startup to use its kit to test for a serious genetic disorder known as Bloom Syndrome.
In November 2013, the FDA ordered 23andMe to stop marketing and selling its kits as a way to test for genetic health information. This marks the first time the FDA has allowed for a home “carrier screening” genetic test. Since the 2013 ban, 23andMe customers could only use the service as a way to find out more about their genealogy.
In a statement on the 23andMe Blog, CEO Anne Wojcicki writes: